81. The Food and Drug Administration (FDA) recommends limiting the use of simvastatin 80 mg because it is known to increase the risk of:
Answer: D
Simvastatin 80 mg is known to increase the risk of muscle damage.
The FDA recommends limiting the use of simvastatin 80 mg due to its association with an increased risk of muscle damage, which can lead to serious conditions such as rhabdomyolysis.
A) severe allergic reactions.
Severe allergic reactions are not commonly linked with simvastatin use. While any medication can potentially cause allergic reactions, the FDA's warnings specifically highlight muscle damage rather than allergic responses.
B) visual disturbances.
Visual disturbances are not a recognized risk associated with simvastatin, and the FDA does not consider them a significant concern in relation to this medication. The focus of the FDA's recommendations is on muscle-related side effects.
C) severe anemia.
Severe anemia is not a known risk associated with simvastatin. The primary safety concerns highlighted by the FDA center around muscle damage, which is more relevant to the medication's adverse effects.
D) muscle damage.
Muscle damage is the primary concern with simvastatin 80 mg, as it can lead to serious complications such as rhabdomyolysis. This risk prompted the FDA's recommendation to limit the dosage to ensure patient safety.
Conclusion
The recommendation to limit simvastatin 80 mg is firmly grounded in the well-documented risk of muscle damage, making option D the only correct choice. Other options fail to address the specific dangers associated with this medication as outlined by the FDA, underscoring the importance of monitoring and managing dosage to protect patient health.